A cell expressing a glycine receptor, its preparation method and application
By employing dual plasmid co-expression technology and gephyrin protein anchoring, the simultaneous and stable expression of GlyR α1 and GlyR β subunits was achieved. Dry-cured cell smears were then prepared, solving the problems of insufficient sensitivity and stability in existing GlyR antibody detection, improving the specificity and repeatability of the detection, and making it suitable for high-specificity GlyR antibody detection.
Patent Information
- Application Number
- CN202611524119.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-29
- Publication Date
- 2026-11-17
AI Technical Summary
Existing GlyR antibody detection methods suffer from problems such as insufficient detection sensitivity, poor repeatability, missing antigenic epitopes, interference from interfering substances, and unstable cell preservation, resulting in high false negative rates and inaccurate test results.
Using dual plasmid co-expression technology, the simultaneous and stable expression of GlyR α1 and GlyR β subunits was achieved through gephyrin protein anchoring and P2A peptide coding sequence, forming a GlyR functional complex consistent with human physiological structure. Dry and cured cell smears were then prepared for the development of a highly specific and stable GlyR antibody detection kit.
It significantly improves the sensitivity and specificity of GlyR antibody detection, reduces false positive and false negative rates, ensures the repeatability of test results and the stability of reagents, and meets the needs of clinical batch testing.
Smart Images

Figure CN123107936A_ABST
Abstract
Description
Technical Field
[0001] This application relates to the field of genetic engineering technology, and in particular to a cell expressing a glycine receptor, its preparation method, and its application. Background Technology
[0002] The glycine receptor (GlyR) is a pentamer protein composed of α1-4 (48kDa) and β subunits (58kDa) forming a homopentamer or heteropentamer. It belongs to the Cys-loop family of pentamer ligand-gated ion channel receptors and is an important cell membrane protein in the central nervous system.
[0003] GlyR is primarily found in the spinal cord, brainstem, and cerebral cortex, where it participates in neurotransmission and precisely regulates functions such as motor control, pain perception, and emotional cognition. As an important inhibitory ion channel receptor, GlyR dysfunction can lead to serious neurological disorders, such as panic disorder, chronic inflammatory pain, alcoholism, and stiff-person syndrome. Anti-GlyR antibodies are pathogenic, recognizing extracellular GlyR sites expressed in the spinal cord, brainstem, and cerebellum, inhibiting normal receptor expression, thereby reducing inhibitory signal transduction in neurons and ultimately leading to increased neuronal excitability. Autoantibodies against the α1 subunit of GlyR have been found in rare diseases such as stiff-person syndrome (SPS) and progressive encephalomyelitis with rigidity and myoclonus (PERM). These antibodies may impair GlyR function, leading to disease symptoms such as muscle spasms and stiffness in the abdominal and limb muscles, suggesting that impaired function of the GlyR α1 subunit may be an important pathological mechanism in these diseases.
[0004] Currently, the mainstream clinical detection method for GlyR antibodies is the indirect immunofluorescence assay based on cell substrates (CBAs). This method is also the gold standard for diagnosing diseases such as autoimmune encephalitis, stiff-person syndrome, and tonic-like paroxysmal encephalomyelitis. However, existing commercially available and laboratory-made CBA test reagents still have many technical shortcomings: Firstly, conventional transient transfection of cells can only express GlyR monomers or some polymers with low efficiency, making it difficult to stably form the natural pentamer spatial conformation. Antibodies mainly recognize conformational epitopes, which can easily lead to the loss of antigenic epitopes, resulting in false negative results and insufficient detection sensitivity. Secondly, the expression levels of engineered cell antigens vary greatly from batch to batch, the cell sheet preparation process is crude, the intensity of positive signals is uneven, and the experimental repeatability is poor. Third, heterophilic antibodies and rheumatoid factor are commonly found in clinical serum and cerebrospinal fluid samples. Existing diluents and blocking systems have weak anti-interference capabilities, high fluorescence background, and are prone to non-specific staining, which interferes with the interpretation of results. Fourth, in the traditional wet slide method, cells are prone to contamination during long-term storage, cells may detach, and they cannot be frozen for preservation, resulting in a short shelf life for cell slides.
[0005] The aforementioned problems severely restrict the clinical application value of GlyR antibody CBA detection reagents. Therefore, there is an urgent need in this field to develop a new generation of GlyR antibody CBA detection kits with high specificity and high stability. Summary of the Invention
[0006] To solve at least one of the above-mentioned technical problems, the technical solution adopted in this application is as follows.
[0007] The first aspect of this application provides a method for preparing cells expressing a glycine receptor, wherein the glycine receptor is composed of an α1 subunit and a β subunit, and the preparation method includes the following steps: A first vector and a second vector are introduced into the cell. The first vector includes a glycine receptor α1 subunit coding sequence and a β subunit coding sequence, and the second vector includes a gephyrin coding sequence.
[0008] Glycine receptors (GlyRs) are transmembrane channels that selectively pass through chloride ions. They regulate chloride ion conductance and membrane polarization through the binding of glycine (a key inhibitory neurotransmitter), and this inhibitory effect is crucial for the normal development and overall function of the central nervous system. The α subunit is the functional subunit of GlyR. Channels composed of the β subunit cannot induce glycine currents, but when α and β are co-expressed, glycine-induced whole-cell currents are greatly increased, suggesting that the β subunit also plays an important role.
[0009] Gephyrin protein can specifically bind to the β subunit of GlyR. After binding, it can facilitate the localization of GlyR on the postsynaptic membrane or slow down the degradation process of the receptor, thereby anchoring GlyR on the cell membrane surface and maintaining the native spatial conformation and physiological localization of GlyR.
[0010] In some embodiments of this application, both the first vector and the second vector are bicistronic expression plasmids containing a strong CMV promoter. In some specific embodiments of this application, the plasmid is a pLVX plasmid.
[0011] In some embodiments of this application, a P2A peptide coding sequence is further included between the α1 subunit coding sequence and the β subunit coding sequence on the first vector. Based on the self-cleaving characteristic of the P2A peptide, independent, synchronous, and efficient expression of the two subunit genes can be achieved under the drive of a single promoter, ensuring a balanced expression ratio between the α1 subunit and the β subunit of GlyR.
[0012] In some specific embodiments of this application, cDNA fragments of the α1 subunit and β subunit of GlyR are ligated by PCR using the P2A peptide coding sequence to form a fusion fragment. The fusion fragment is then homologously recombinated with a plasmid. After the ligation product is transformed into DH5α competent cells, clones are selected for colony PCR, enzyme digestion, and sequencing verification to finally obtain the first vector co-expressing the α1 subunit and β subunit of GlyR.
[0013] In some embodiments of this application, during the preparation process, the second vector is first transferred into the cells, followed by the first vector. Using this method, a higher expression level can be obtained compared to transferring the first vector first and then the second vector.
[0014] In some specific embodiments of this application, both the first vector and the second vector are lentiviral vectors. First, the host cell is transfected with the second vector, which includes the gephyrin coding sequence. Utilizing the gephyrin vector's genome integration capability, the gephyrin coding sequence is recombined and integrated into the host cell's genome, constructing a host cell stably expressing the gephyrin protein. Then, the host cell expressing the gephyrin protein is transfected with the first vector, which includes the coding sequences for the α1 and β subunits of GlyR.
[0015] The second aspect of this application provides cells or products thereof prepared using any of the preparation methods described in the first aspect of this application.
[0016] The third aspect of this application provides the use of the cells or their products described in the second aspect of this application in the preparation of a kit for detecting glycine receptor antibodies in biological samples.
[0017] The fourth aspect of this application provides a kit for detecting glycine receptor antibodies in biological samples, the kit comprising any of the cells or products thereof described in the third aspect of this application.
[0018] In some embodiments of this application, the cell product is a cell spreader.
[0019] In some embodiments of this application, the cell-crawling slab is prepared as follows: Add cell adhesion reagent to a cell culture dish, place cell crawling slides in the dish, incubate, discard the working solution of the adhesion reagent, wash and set aside; The cells were seeded into a cell culture dish containing complete culture medium and cultured until the cell growth density reached more than 90%. Then, the cells were digested from the culture dish and the cell suspension was collected. 500µL of the cell suspension was added to a culture dish containing a cell spreader and cultured to allow the cells to adhere to the spreader and grow. After the cell slide culture is completed, the culture medium is removed, the slide is washed, fixed with paraformaldehyde, washed again, and then vacuum dried.
[0020] In some embodiments of this application, the cell slices of appropriate size are cut and attached to a planar carrier.
[0021] In some embodiments of this application, the biological sample is selected from serum samples and cerebrospinal fluid.
[0022] Compared with the prior art, this application has the following advantages: This application utilizes dual plasmid co-expression technology to simultaneously express the GlyR α1 and GlyR β subunits and stably express the gephyrin-anchored protein. Thanks to the promoting effect of gephyrin on the membrane transport of GlyR protein, a GlyR functional complex consistent with the physiological structure of the human body is assembled. The receptor membrane is normally positioned and the conformation is intact, which can specifically recognize functional GlyR antibodies, significantly reducing the false positive and false negative rates. The detection sensitivity and specificity are significantly better than traditional detection reagents that only express the GlyR α1 subunit antigen.
[0023] This application uses stable cell lines instead of traditional transient transfection cells. After antibiotic screening and monoclonal purification, the cells are stable and the target protein is continuously and stably expressed, which completely solves the problems of large batch differences and protein expression fluctuations in transient transfection. The reagent detection results have excellent repeatability.
[0024] Compared with conventional transient transfection methods, the cell lines prepared by the method provided in this application mimic the relevant functions of natural GlyR, can ensure the consistency of different batches of cells, and do not require frequent cell transfection, thus greatly saving time and economic costs.
[0025] This application prepares cell slides into dried and solidified cell slides, which enhances reagent stability and extends the shelf life of reagents compared to fresh cell slides, significantly reducing transportation and storage costs and meeting the needs of clinical batch testing.
[0026] It should be understood that the description in this section is not intended to identify key or essential features of the embodiments of this application, nor is it intended to limit the scope of this application. Other features of this application will become readily apparent from the following description. Attached Figure Description
[0027] The above and other objects, features, and advantages of exemplary embodiments of this application will become readily apparent from the accompanying drawings and the following detailed description. Several embodiments of this application are illustrated in the drawings by way of example and not limitation, wherein: Figure 1The results of testing sample 3 with pLVX-GlyRα1 cells and pLVX-GlyRα2 cells in Example 1 of this application are shown; Figure 2 The detection results of different subunit combinations in Embodiment 2 of this application are shown; Figure 3 The detection results of different mass ratios of GlyRα1 and GlyRβ combinations in Example 2 of this application are shown; Figure 4 The detection results of different subunit combinations in Embodiment 3 of this application are shown; Figure 5 The detection results of different transfection methods of GlyRα1 and GlyRβ in Example 4 of this application are shown; Figure 6 The detection results of different transfection sequences of GlyRα1-P2A-GlyRβ and gephyrin in Example 4 of this application are shown; Figure 7 A schematic diagram of the cell smear distribution prepared in Example 5 of this application is shown, where 1 represents the experimental area and 2 represents the control area.
[0028] Figure 8 The results of positive and negative serum and cerebrospinal fluid samples in Example 6 of this application are shown; Figure 9 The results of three groups of cell smear detection of clinical serum samples in Example 6 of this application are shown, wherein S1 and S2 represent clinical samples with different titers; Figure 10 The results of three groups of cell smear tests on clinical cerebrospinal fluid samples in Example 6 of this application are shown, where C1 and C2 represent clinical samples with different titers. Detailed Implementation
[0029] Unless otherwise stated, implied from the context, or as is customary in the art, all parts and percentages in this application are based on weight, and all testing and characterization methods used are concurrent with the filing date of this application. Where applicable, any patent, patent application, or disclosure relating to this application is incorporated herein by reference in its entirety, and its equivalent patent families are also incorporated herein by reference, particularly the definitions of relevant terms in the art disclosed in such documents. If any definition of a specific term disclosed in the prior art is inconsistent with any definition provided in this application, the definition provided in this application shall prevail.
[0030] To make the technical problems, technical solutions and beneficial effects solved by this application clearer, the following detailed description is provided in conjunction with embodiments.
[0031] The following examples are used to illustrate preferred embodiments of this application. Those skilled in the art will understand that the techniques disclosed in the examples represent technologies discovered by the inventors that can be used to implement this application, and therefore can be considered preferred embodiments of this application. However, those skilled in the art should understand from this specification that many modifications can be made to the specific embodiments disclosed herein, still yielding the same or similar results, without departing from the spirit or scope of this application.
[0032] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application pertains, and all publicly cited and referenced material herein is incorporated herein by reference.
[0033] Those skilled in the art will recognize, or can learn through routine experimentation, many equivalents of the specific embodiments of the invention described herein. These equivalents will be included in the claims.
[0034] Unless otherwise specified, the experimental methods used in the following examples are conventional methods. Unless otherwise specified, the instruments and equipment used in the following examples are all conventional laboratory instruments and equipment; unless otherwise specified, the experimental materials used in the following examples were all purchased from conventional biochemical reagent stores.
[0035] Example 1: Validation and Determination of Target Antigen Sequence 1. Design of specific amplification primers Based on the coding sequences of GlyRα1, GlyRα2, and GlyRβ (as shown in SEQ ID No. 1, SEQ ID No. 2, and SEQ ID No. 3, respectively), specific primer pairs for amplifying the full-length sequences were designed. Simultaneously, specific primer pairs for amplifying the truncated sequences ECD, Epi1, and Epi2 (as shown in SEQ ID No. 4, SEQ ID No. 5, and SEQ ID No. 6, respectively) of GlyRα1 were designed. The specific primers are shown in Table 1.
[0036] Table 1: Specific amplification primers .
[0037] 2. Construction of pLVX-GlyRα1, pLVX-GlyRα2 and pLVX-GlyRβ plasmids Using human brain tissue cDNA as a template, the target sequences were amplified using the primer pairs corresponding to Table 1. The PCR products were recovered and purified, and the recovered products were double-digested with the pLVX-CMV vector (purchased from NovoPro) using XhoI and BamHI, respectively. After the digestion products were recovered, purified, and ligated, the constructed plasmids were transformed, subjected to bacterial culture PCR, sequencing, and culture, and then amplified and extracted to obtain pLVX-GlyRα1, pLVX-GlyRα2, and pLVX-GlyRβ plasmids, respectively.
[0038] 3. Construction of pLVX-ECD, pLVX-Epi1, and pLVX-Epi2 plasmids Using the amplified GlyRα1 coding sequence as a template, truncated fragments of GlyRα1 at different positions were amplified using the primer pairs corresponding to Table 1. These fragments were then double-digested with XhoI and BamHI, and the digestion products were recovered, purified, and ligated. The constructed plasmids were then transformed, subjected to bacterial PCR, sequencing, and culture, and amplified and extracted to obtain pLVX-ECD, pLVX-Epi1, and pLVX-Epi2 plasmids, respectively.
[0039] 4. Validation of antigen detection performance 1) Transfection HEK293T cells were loaded at approximately 8 × 10⁻⁶ 5 Cells were seeded at a density of 10 cells / well in 6-well plates and incubated overnight at 37°C with 5% CO2. When the cell confluence reached approximately 70%, transfection was prepared.
[0040] Prepare transfection mixtures containing 2 μg of target plasmid DNA, 4 μg of PEI (Polysciences, 24765), and 2 mL of fresh DMEM medium per well. Vortex mix thoroughly and incubate at room temperature for 25 min. Add the corresponding transfection mixture to the corresponding wells and transfect the above 6 plasmids into HEK293T cells respectively (different plasmids transfect different cells). After culturing for 4–6 h, replace with fresh complete DMEM medium and continue culturing for 18–20 h.
[0041] 2) planking After culturing, the cells were digested from the culture dish using Trypsin-EDTA (Gibco, 15140163), and the cell suspension was adjusted to a cell density of 3 × 10⁶ cells / mL using complete culture medium. 6 Cells / mL were added to each well of a 96-well plate with 100 µL of cell suspension and cultured at 37°C and 5% CO2 for 12–16 hours.
[0042] 3) Fix The culture medium was aspirated, and the cells were washed with sterile 1×PBS. Then, 4% paraformaldehyde was added, and the cells were fixed at room temperature for 20 minutes. The cells were washed three times with sterile 1×PBS to obtain a total of six different types of fixed cells.
[0043] 4) Detection Six serum samples that were positive for GlyR antibodies were prepared and tested using the six types of fixed cells mentioned above. These samples were tested by Taizhen (Jiangsu) Medical Laboratory Co., Ltd. using the LCBA (cell substrate immunofluorescence assay) method for human GlyRα1 expression. The samples were determined to be GlyR antibody positive by this method. Other relevant samples were also tested by Taizhen.
[0044] The testing process is as follows: Sample processing: Dilute the serum sample 10 times with blocking buffer (goat serum, Sijiqing, 50010-8615) and set aside; Sample incubation: Add 100µL of the sample to be tested to the corresponding well of the 96-well plate and incubate at 37℃ for 35 min; Washing: After incubation, aspirate the sample to be tested, add 100µL of washing solution (phosphate buffer, Biosharp, BL601A) for washing, wash 3 times, and after the last wash, let stand for 5 minutes and then aspirate the washing solution. Secondary antibody incubation: The fluorescent secondary antibody was Alexa fluor 488-labeled goat anti-human IgG (Invitrogen). 100µL of fluorescent secondary antibody was added to the cell smear reaction area to ensure that the secondary antibody fully covered the reaction area. The cells were incubated at 37°C in the dark for 35 minutes. Washing: After incubation, remove the secondary antibody, add 100µL of washing solution for washing, wash 3 times, and after the last wash, let stand for 5 minutes and then aspirate the washing solution. Results determination: 100µL of washing solution was added, and the green fluorescence of the cells was observed under a fluorescence microscope and photographed.
[0045] The test results are shown in Table 2.
[0046] Table 2: Comparison of Detection Results for Different Cells .
[0047] Note: In the table, “√” indicates a positive signal was detected, and “×” indicates no positive signal was detected.
[0048] As shown in Table 2, since the antigen-binding site of the GlyR antibody is mainly located in the extracellular domain of the GlyRα1 subunit, pLVX-GlyRα1 cells had the highest detection rate; pLVX-GlyRα2 cells could only detect a very small number of samples, and pLVX-GlyRα1 cells could also be detected (e.g., Figure 1Due to epitope mismatch, no positive signal was detected in any pLVX-GlyRβ cell samples; cells containing pLVX-ECD, pLVX-Epi1, and pLVX-Epi2 may not correctly express the assembly epitope, and therefore could not be detected in all samples (e.g. Figure 1 ).
[0049] However, although cells containing pLVX-GlyRα1 had the highest detection rate, they could not be detected 100%, and the detection titer did not meet expectations, requiring further optimization.
[0050] Example 2: The effect of different GlyR subunit combinations and ratios on detection results Considering that the complete structure of the glycine receptor is a pentamer composed of α1~α4 and β, this embodiment tests whether the α2 subunit and β subunit can assist in the synthesis and transfer of the receptor protein. The inventors combined the α1 subunit, α2 subunit and β subunit of GlyR and detected GlyR antibodies respectively to compare the detection performance of different combinations.
[0051] Specifically, the instantaneous rotation system was used to verify the results of sample detection for different subunit combinations, as shown in Table 3.
[0052] Table 3: Experimental groups with different subunit combinations .
[0053] Note: Except for a few validation groups, the total amount of plasmid used and the amount of PEI used follow a mass ratio of 1:3.
[0054] The results are as follows Figure 2 As shown, among the different subunit combinations, compared to group 2, with the same PEI dosage, appropriately increasing the amount of α1 subunit stroma granules resulted in better transfection and more positive cells. Compared to group 2, groups 3 / 4 / 5, with the same PEI dosage ratio, all showed significantly better detection results and stronger positive signals, indicating that the α2 and β subunits promote the correct expression of the receptor protein. Among groups 3 / 4 / 5, the results of groups 4 and 5 were comparable, but both were superior to group 3. It is preliminarily determined that compared to the combination of α1 and α2 subunits, the combination of α1 and β subunits results in better receptor protein assembly.
[0055] Furthermore, the inventors compared the effects of different ratios of α1 subunit and β subunit dosages, as well as the ratio of the total dosage of α1 subunit and β subunit to the PEI dosage, on the detection results, using Group 1 and Group 2 as controls. The experimental setup is shown in Table 4.
[0056] Table 4: Experimental groups with different mass ratios of α1 subunit and β subunit .
[0057] Note: The total amount of target plasmid used in groups 1-4 and the amount of PEI used follow a mass ratio of 1:3, and the ratio for groups 5-6 is 1:4.
[0058] The results are as follows Figure 3 As shown, consistent with previous results, Group 2 results were better than Group 1, and the combination of α1 subunit and β subunit yielded better detection results than α1 subunit alone. Compared with Groups 3 / 4 / 5 / 6, Groups 4 and 6 had comparable results and were better than Groups 3 and 5, indicating that regardless of whether the total amount of α1 subunit and β subunit is used in a PEI mass ratio of 1:3 or 1:4, a 1:1 mass ratio of α1 subunit and β subunit yielded better detection results.
[0059] Example 3: The effect of combining GlyR's α1 subunit, β subunit, and gephyrin on detection results In this embodiment, the inventors combined the α1 subunit, β subunit, and gephyrin of GlyR and detected GlyR antibodies separately to compare the detection performance of different combinations.
[0060] 1. Construction of pLVX-gephyrin plasmid Design full-length specific amplification primers for gephyrin based on its coding sequence (e.g., SEQ ID No. 16).
[0061] GF (5'-3'): CCGGAATTCATGGCGACCGAGGGAATGATC (SEQ ID No. 17) GR (5'-3'): GCTTCTAGATCATAGCCGTCCAATGACCATGAC (SEQ ID No. 18) Using human brain tissue cDNA as a template, the target sequence was amplified using GF and GR. The PCR product was recovered and purified, and the recovered product and pLVX-CMV vector (purchased from NovoPro) were double-digested with EcoRI and XbaI, respectively. After the digestion products were recovered, purified, and ligated, the constructed plasmid was transformed, subjected to bacterial culture PCR, sequencing, and culture, and then amplified and extracted to obtain the pLVX-gephyrin plasmid.
[0062] The same instantaneous rotation system was used to verify the results of sample detection for different subunit combinations. The dosage of different subunit combinations is shown in Table 5.
[0063] Table 5: Experimental groups with different subunit combinations .
[0064] Test results as follows Figure 4As shown, samples from group 4 (gephyrin alone) and group 5 (gephyrin and β subunit combination) were all negative, indicating that they could not specifically bind to GlyR antibody, meaning that GlyR antibody could not be detected alone. Furthermore, the detection results of the combination of α1 subunit, β subunit and gephyrin tri-subunit were better than those of the α1 subunit and β subunit combination, and better than those of the α1 subunit and gephyrin combination, indicating that the tri-subunit combination was more effective.
[0065] Example 4: Construction of GlyR α1 subunit and β subunit stable translocation system To determine the optimal stabilization modes and conditions for the α and β subunits of GlyR and the gephyrin trisubunit, the inventors constructed different stabilization modes, as follows.
[0066] Group 1: Transfected only with GlyRα1 pseudovirus suspension; Group 2: First transfect GlyRα1 pseudovirus suspension, then transfect GlyRβ pseudovirus suspension; Group 3: First transfect GlyRβ pseudovirus suspension, then transfect GlyRα1 pseudovirus suspension; Group 4: Transfection with a mixed suspension of GlyRα1 and GlyRβ.
[0067] The method for preparing the pseudovirus suspension is as follows: Solution A and solution B were prepared. Solution A consisted of 500 μL of serum-free medium (Gibco, 31985-070), with psPAX2 and pMD2.G packaging plasmids added. After thorough mixing, the corresponding plasmids were added, and the mixture was incubated at room temperature for 5 min. Solution B consisted of 500 μL of serum-free medium with 30 μL of PEI solution (Polysciences, 24765), and incubated at room temperature for 5 min. Solution A and solution B were then thoroughly mixed and incubated for 25 min. The old medium in the cells was replaced with fresh medium. The mixture of solutions A and B was added along the wall of the culture dish, and the cells were incubated for 4-6 h. The medium was then changed, and medium containing 10% FBS was added. After incubation for another 48 h, the medium was filtered through a 0.45 μm filter and collected to obtain the corresponding pseudovirus suspension. A pseudovirus suspension was also prepared using the empty pLVX plasmid as a negative control.
[0068] HEK293T cells were seeded in 6 cm culture dishes, with a total cell volume of 3 × 10⁻⁶ cells. 6Cells / plate were cultured for 18-20 hours until cell confluence reached approximately 80-90%. HEK293T cells were seeded into 6-well plates. When cell confluence reached approximately 30-40%, the old culture medium was aspirated, and 1.5 mL of fresh serum-free culture medium was added. Then, 1.5 mL of pseudovirus suspension was slowly added, along with 3 μL of polystyrene gel (BioSharp, BL628A). After mixing, the cells were cultured for 48 hours, and then the medium was replaced with complete medium (DMEM:FBS:antibody = 45:5:0.5, v / v / v). Subsequent selection was performed using antibiotics to determine stable gene expression. Following the above method, cells containing the empty pLVX plasmid pseudovirus suspension were prepared as a control.
[0069] The results are as follows Figure 5 As shown, the recombination and integration efficiency of GlyRβ pseudovirus suspension after transfection into HEK293T cells is much higher than that of GlyRα1. Therefore, the number of cells in groups 3 and 4 that can correctly express GlyRα1 is very small, and the detection results are poor.
[0070] To control the expression of GlyRα1 and GlyRβ, the inventors fused the two for expression. Specifically, they constructed the pLVX-GlyRα1-P2A-GlyRβ plasmid and conducted a stable transduction test. The construction method of the pLVX-GlyRα1-P2A-GlyRβ plasmid is as follows.
[0071] Using human brain tissue cDNA as a template, the GlyRα1 sequence was first amplified using primers A1P-F and A1P-R (Table 6), and the GlyRβ sequence was amplified using primers BP-F and BP-R. The GlyRα1 and GlyRβ sequences were then combined and used as a template for fusion PCR amplification using primers A1P-F and BP-R (Table 6), resulting in the fusion fragment GlyRα1-P2A-GlyRβ, thus introducing the P2A sequence between the GlyRα1 and GlyRβ sequences. The nucleotide sequence of P2A is shown in SEQ ID No. 19. The amplified product had restriction sites XhoI (5' end) and NotI (3' end) at both ends. The PCR product was recovered and purified.
[0072] Table 6: Primer information used to construct GlyRα1-P2A-GlyRβ .
[0073] The fusion fragment GlyRα1-P2A-GlyRβ and the pLVX vector containing the strong constitutive promoter CMV were double-digested with XhoI and NotI, respectively. The digested products were then purified and recovered. The fusion fragment and the vector were ligated using a ligase. The constructed plasmid was then transformed into DH5α competent cells. After colony PCR, sequencing, and shaking, amplification and extraction were performed to obtain the pCMV-GlyRα1-P2A-GlyRβ plasmid.
[0074] The inventors further compared the following two stable rotation methods.
[0075] Group 5: First convert gephyrin, then convert GlyRα1-P2A-GlyRβ; Group 6: First convert GlyRα1-P2A-GlyRβ, then convert gephyrin.
[0076] Cells obtained using different stabilization methods were tested for GlyR antibodies, and the results are as follows: Figure 6 As shown, the detection results of group 5 are good, comparable to the instantaneous transfection combination, while the detection results of group 6 are relatively poor, indicating that the transfection order affects protein expression and ultimately affects the detection results.
[0077] Example 5: Preparation of HEK293T cell smears containing GlyRα1 / β type GlyR 1. Pretreatment of cell slides Add 5 mL of adhesion reagent working solution (prepared with Prilele C1010) to a 6 cm diameter round cell culture dish, place a 10*10 mm cell spreader (Abixin) on it, incubate at 37℃ for 1 h or at room temperature for 4-6 h, then discard the adhesion reagent working solution, wash the spreader once with 1*PBS for 5 min, so that HEK293T cells are suitable for attachment and growth on the cell spreader.
[0078] 2. Preparation of cell smears The co-transfected HEK293T cells and empty HEK293T cells were seeded into 6cm round cell culture dishes containing complete culture medium and cultured at 37°C and 5% CO2 until the cell density reached over 90%. The cells were then digested with Trypsin-EDTA (Gibco) and 3×10⁶ cells were collected. 6 Add 1 mL of cell suspension per mL to a culture dish containing the pretreated cell spreader, and incubate overnight at 37°C with 5% CO2 to allow the cells to adhere to the spreader and grow.
[0079] 3. Cell fixation After the cell smear culture was completed, the culture medium was aspirated, and the cells were washed with sterile 1*PBS. Then, 4% paraformaldehyde was added, and the cells were fixed at room temperature for 20 minutes. The cells were washed three times with sterile 1*PBS, the liquid was aspirated, and a desiccant (trehalose 80 g / L, sucrose 30 g / L, mannitol 5% (v / L), hydroxyethyl starch 30 g / L, BSA 40 g / L, sodium carboxymethyl cellulose 40 g / L, polyvinylpyrrolidone 40 g / L, cysteine 10 g / L, sodium citrate 5-7 g / L) was added to cover the cell smears. The cells were incubated at 37°C for 2 hours, and then vacuum dried. The cell smears were cut into 5mm squares using a glass cutter. The cut GlyR(+)HEK293T smears and coverslips GlyR(-)HEK293T smears were then attached to the same side of a glass slide (Shitai, 80383-0004-01) using UV adhesive to create the reaction zone (i.e.,...). Figure 7 Cell slides were prepared in two sections (sections 1 and 2, with section 1 being the experimental section and section 2 being the control section). Each slide was individually vacuum-sealed and stored at -20℃±5℃.
[0080] Example 6: Detection of GlyR-IgG in serum and cerebrospinal fluid samples using cell smears The cell smears prepared in Example 5 can be further packaged into a kit for detecting GlyR-IgG in clinical samples. In addition to the cell smears, the kit includes blocking solution (goat serum, Sijiqing, 50010-8615), washing solution (phosphate buffer, Biosharp, BL601A) and fluorescent secondary antibody. The fluorescent secondary antibody is goat anti-human IgG (Invitrogen) labeled with Alexa fluor 488. The specific specifications and components are shown in Table 7.
[0081] Table 7: Kit Components .
[0082] To demonstrate the detection results of cell slides, the inventors prepared three types of cell slides: cell slides expressing GlyRα1, cell slides expressing GlyRα1 and β (obtained by transfecting GlyRα1-P2A-GlyRβ), and cell slides expressing GlyRα1, β, and gephyrin (obtained by first transfecting gephyrin and then transfecting GlyRα1-P2A-GlyRβ).
[0083] Furthermore, the CBA method was used to detect GlyR-IgG in blood and cerebrospinal fluid samples. The specific process is as follows: (1) Preparation of cell slides: Remove the cell slides from the cryolayer, equilibrate to room temperature, add 100µL of washing solution to the reaction area (make sure the reaction area is completely covered), let stand at room temperature for 5 minutes, and then aspirate the liquid. (2) Sample processing: Dilute serum samples 10 times with blocking solution and set aside; cerebrospinal fluid does not need to be diluted; (3) Sample incubation: Add 100µL of the sample to be tested to the cell smear reaction area, ensuring that the sample fully covers the reaction area, and incubate at 37℃ for 35min; (4) Washing: After incubation, aspirate the sample and add 100µL of washing solution for washing. Wash 3 times. After the last wash, let stand for 5 minutes and then aspirate the washing solution. (5) Secondary antibody incubation: Add 100µL of fluorescent secondary antibody to the cell smear reaction area, ensuring that the secondary antibody fully covers the reaction area, and incubate at 37°C in the dark for 35 min; (6) Washing: After incubation, remove the secondary antibody and add 100µL of washing solution for washing. Wash 3 times. After the last wash, let stand for 5 minutes and then wipe off the washing solution. (7) Result determination: Add 100µL of washing solution to the cell smear reaction area, then observe the green fluorescence of the cells under a fluorescence microscope and take a picture.
[0084] Sample positive: Zone 1 should be positive, showing bright fluorescent green cells with altered cell morphology; Zone 2 should be negative, with no fluorescent green cells observed and no cell morphology changes. Sample negative: Zone 1 should be negative, with no bright fluorescent green cells observed and no changes in cell morphology; Zone 2 should be negative, with no bright fluorescent green cells observed and no changes in cell morphology (e.g., Figure 8 (As shown).
[0085] Three types of cell smears were used to test clinical samples, and the detection effects of different groups were compared. A total of 83 clinical samples were selected, including 28 positive serum (PS), 26 positive cerebrospinal fluid (PC), 16 negative serum (NS), and 13 negative cerebrospinal fluid (NC). The fluorescence intensity of the results images of the clinical positive samples was analyzed using ImageJ software (as shown in Table 8), and they were divided into moderately strong positive and weakly positive samples for statistical analysis.
[0086] Table 8: Sample Grade Classification Criteria .
[0087] The above clinical samples were tested using three sets of reagents. The specific test results are shown in Table 9 below, and the microscopic images are as follows. Figure 9 , Figure 10 As shown.
[0088] Table 9: Comparison of results from three groups of cell smear detection .
[0089] From Table 9, Figure 9 and Figure 10 It can be seen that the negative detection rate of the three types of cell smear samples was 100%, with good specificity; the positive rate of cell smears expressing the α1 subunit, β subunit and gephyrin was 100%, with the highest sensitivity; the positive rate of cell smears expressing the α1 subunit and β subunit was 94.4%; and the positive rate of cell smears expressing the α1 subunit was 83.3%.
[0090] The inventors further analyzed that the co-transformation of the α1 and β subunits of GlyR can better restore the native conformation of the glycine receptor protein; gephyrin further promotes the correct folding and transport of the receptor protein onto the membrane, thereby improving the sensitivity of detection.
[0091] Example 7: Precision test results of different batches of reagent kits Three batches of cell slices expressing the α1 subunit, β subunit, and gephyrin of GlyR were produced consecutively, and reagent kits were prepared. Two positive samples were tested, with each sample tested 10 times per batch. The fluorescence intensity of the test images was analyzed using ImageJ software. The coefficient of variation among the three batches of reagents was calculated to determine the repeatability of different batches of reagents. The results are shown in Table 10.
[0092] Table 10: Precision test results of three batches of reagents .
[0093] As shown in Table 10, the intra-batch and inter-batch precision of the three batches of cell slides were all ≤10%, indicating good intra-batch and inter-batch reproducibility and good inter-batch stability of cell slides.
[0094] Example 8: Results of reagent kit stability test The kit was stored at -20℃±5℃, and its detection performance was tested at 3, 6, 9, 12, and 13 months of storage. A total of 30 clinical samples (including 15 positive serum samples and 15 negative serum samples) were selected for testing, and the specific test results are shown in Table 11 below.
[0095] Table 11: Storage Stability Test Results .
[0096] As shown in Table 11, the detection accuracy of the kit for both positive and negative samples was 100% within 13 months of storage, indicating that the kit can be stored at -20℃±5℃ for 12 months and has good stability.
[0097] Furthermore, it should be understood that after reading the foregoing content of this application, those skilled in the art can make various alterations or modifications to this application, and these equivalent forms also fall within the scope defined by the appended claims.
Claims
1. A method for preparing cells expressing a glycine receptor, wherein the glycine receptor is composed of its α1 subunit and β subunit, characterized in that, Includes the following steps: A first vector and a second vector are introduced into the cell. The first vector includes a glycine receptor α1 subunit coding sequence and a β subunit coding sequence, and the second vector includes a gephyrin coding sequence.
2. The preparation method according to claim 1, characterized in that, On the first vector, between the α1 subunit coding sequence and the β subunit coding sequence, there is also a P2A peptide coding sequence.
3. The preparation method according to claim 1 or 2, characterized in that, During the preparation process, the second vector is first transferred into the cells, followed by the first vector.
4. Cells or their products prepared using any of the preparation methods described in claims 1 to 3.
5. The use of the cell or its product according to claim 4 in the preparation of a kit for detecting glycine receptor antibodies in biological samples.
6. A kit for detecting glycine receptor antibodies in biological samples, characterized in that, The kit comprises the cells or products thereof as described in claim 4.
7. The reagent kit according to claim 6, characterized in that, The product made from the cells is a cell spreader.
8. The reagent kit according to claim 7, characterized in that, The method for preparing the cell-crawling slide is as follows: Add cell adhesion reagent to a cell culture dish, place cell crawling slides in the dish, incubate, discard the working solution of the adhesion reagent, wash and set aside; The cells were seeded into a cell culture dish containing complete culture medium and cultured until the cell growth density reached more than 90%. Then, the cells were digested from the culture dish and the cell suspension was collected. 500µL of the cell suspension was added to a culture dish containing a cell spreader and cultured to allow the cells to adhere to the spreader and grow. After the cell slide culture is completed, the culture medium is removed, the slide is washed, fixed with paraformaldehyde, washed again, and then vacuum dried.
9. The reagent kit according to claim 7, characterized in that, Cut an appropriate size of the cell slice and attach it to a planar carrier.
10. The kit according to any one of claims 7 to 9, characterized in that, The biological sample is selected from either serum or cerebrospinal fluid.
